What is the formula to calculate the FIB-4 (Fibrosis-4) score in a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 16, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Calculate the FIB-4 Score

Formula

The FIB-4 score is calculated using the formula: Age (years) × AST (IU/L) / [Platelet count (×10⁹/L) × √ALT (IU/L)] 1

Required Laboratory Values

To calculate FIB-4, you need exactly four values 1:

  • Age in years
  • AST (aspartate aminotransferase) in IU/L
  • ALT (alanine aminotransferase) in IU/L
  • Platelet count in ×10⁹/L (or multiply by 10⁹ if given in cells/μL)

Step-by-Step Calculation Example

  1. Multiply the patient's age by their AST level 1
  2. Take the square root of the ALT value 1
  3. Multiply the platelet count by the square root of ALT 1
  4. Divide the result from step 1 by the result from step 3 1

For instance, a 55-year-old patient with AST 45 IU/L, ALT 36 IU/L, and platelets 180 × 10⁹/L would have: (55 × 45) / (180 × √36) = 2475 / (180 × 6) = 2475 / 1080 = 2.29

Interpretation of Results

Once calculated, interpret the FIB-4 score using age-adjusted cutoffs 1, 2:

  • FIB-4 <1.3 (or <2.0 if age ≥65 years): Low probability of advanced fibrosis with approximately 90% negative predictive value—repeat testing in 2-3 years 1, 2

  • FIB-4 1.3-2.67: Indeterminate range requiring additional testing such as vibration-controlled transient elastography (FibroScan) or Enhanced Liver Fibrosis (ELF) testing 1, 2

  • FIB-4 >2.67: High probability of advanced fibrosis with approximately 60-80% positive predictive value—refer to hepatology for comprehensive evaluation 1, 2

Age-Specific Cutoff Refinements

For patients ≥60 years, age-adjusted cutoffs improve diagnostic accuracy 3:

  • Ages ≤49 years: Low cutoff 1.05, high cutoff 1.21 3
  • Ages 50-59 years: Low cutoff 1.24, high cutoff 1.96 3
  • Ages 60-69 years: Low cutoff 1.88, high cutoff 2.67 3
  • Ages ≥70 years: Low cutoff 1.95, high cutoff 2.67 3

These age-modified cutoffs reduce false-positive rates in elderly patients while maintaining sensitivity 3.

Clinical Performance Characteristics

The FIB-4 index demonstrates 4, 1:

  • AUROC of 0.77-0.90 for detecting advanced fibrosis depending on the population studied 4
  • Excellent negative predictive value (>90%) for ruling out advanced fibrosis 1
  • Moderate positive predictive value (60-80%) for confirming advanced disease 2

Important Limitations and Pitfalls

Age significantly affects FIB-4 values, causing the score to naturally increase with age, leading to higher false-positive rates in elderly patients and potential false-negatives in younger patients 1. Always use the higher cutoff (<2.0) for patients ≥65 years to avoid overestimating fibrosis risk 2.

FIB-4 measures liver enzyme levels, which can generate false-positive results in patients with acute hepatitis independent of the degree of liver fibrosis 4. Avoid calculating FIB-4 during acute hepatic inflammation or flares of chronic liver disease.

The score performs poorly in patients younger than 35 years and may require adjusted cutoffs 2. Consider alternative testing modalities in very young patients.

Monitoring Fibrosis Progression Over Time

Serial FIB-4 measurements can track fibrosis progression 5. An increase in the ΔFIB-4 index per year ≥0.4 predicts progression to cirrhosis with an AUROC of 0.910, while ΔFIB-4/year <0.4 indicates stable disease 5. The cumulative incidence of progression to cirrhosis at 10 years is 59% with ΔFIB-4/year ≥0.4 versus only 3% with ΔFIB-4/year <0.4 5.

References

Guideline

FIB-4 Score Calculation and Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

FIB-4 Score Applications and Interpretations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.